Bio-S: Innovative drug BIOS-0623-Z4 tablets have received clinical trial approval
Bio-S announced that its independently developed innovative drug BIOS-0623-Z4 tablets have received clinical trial approval from the National Medical Products Administration (NMPA). This drug targets cancer pain in adults and employs a non-opioid target mechanism, with no other drugs on the market targeting the same mechanism and indication. BIOS-0623-Z4 tablets are classified as Category 1 chemical drugs and are innovative drugs that have not been launched domestically or internationally
According to the Zhitong Finance APP, Bio-S (301096.SZ) announced that the company recently learned that its independently developed innovative drug BIOS-0623-Z4 tablets received the clinical trial approval notice from the National Medical Products Administration (NMPA).
BIOS-0623-Z4 tablets are a non-opioid targeted mechanism drug developed by the company for the treatment of cancer pain in adults, and currently, there are no drugs on the market with the same target and indication. BIOS-0623-Z4 tablets are classified as an "innovative drug that has not been marketed domestically or internationally," and its registration classification is Category 1 chemical drugs
